European Commission President Ursula von der Leyen said the EU had already exported more than a billion vaccines against Covid-19 to more than 150 countries around the world. “It is very clear that the European Union is the largest exporter of coronavirus vaccines,” Von der Layen said, adding that support for third countries was similar to that provided to EU member states. trial of its Covid vaccine The French-Austrian company Valneva announced today that it has positive results from the “Phase 3” trial of its vaccine against measles … Read more According to the European Center for Disease Prevention and Control nearly 80% of EU citizens at the age of 18 and over have received at least one dose of vaccine since the beginning of the vaccination campaign against Covid 19. Bulgaria continues to lag far behind, ranking last in the EU with only 25% of vaccines with at least one dose.
Meanwhile, scientists at Oxford University have begun work on modifying their vaccine against COVID-19 to make it more effective against the Delta variant. This was reported by The Independent. The new preparation is being worked on by members of Professor Sarah Gilbert’s team – the scientists who developed the AstraZeneca vaccine, the publication writes. A source told The Independent that the new vaccine is designed to “have something ready on the shelf – if necessary.” The incidence of the Delta variant is increasing again on the Island. About 49,156 people tested positive for coronavirus on Monday, an increase of 22% on a weekly basis and the highest level since the end of the lockdown in the country.
The increase in prevalence comes amid declining levels of protection among older age groups.
Experts say there is “reason” for Delta-specific vaccines to be used for current and future vaccination programs, as the option now accounts for most of the world’s infections. The source from Oxford said that the work of scientists in the development of the new vaccine is at a very early stage, but clarified that it will not be difficult to make the necessary modifications, given the nature of the technology behind the vaccine. However, he stressed that even the “subtle changes” introduced into the production process as a result of the transition to a modified vaccine could cause significant delays and prevent the global spread of life-saving doses, at a time when millions of people remain unvaccinated.
